BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-317@pharmaconomics
DTSTAMP:20260707T015436Z
DTSTART;VALUE=DATE:20260501
DTEND;VALUE=DATE:20260502
SUMMARY:OTLK PDUFA — ONS-5010/LYTENAVA (estimated date)
DESCRIPTION:The FDA's approval decision on ONS-5010/LYTENAVA for neovascular age-related macular degeneration (nAMD) is due ~ May 1\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1649989/000110465926040387/tm2611268d1_ex99-1.htm\n\nTrack it: https://pharmaconomics.com/e/317
URL:https://pharmaconomics.com/e/317
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:OTLK catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR